Avicanna Files Patent After Positive Oral Absorption Study

Avicanna Reports Positive Preclinical Data and Provisional Patent Filing for Novel Oral Cannabinoid Delivery Platform

PwdRx Platform Developed to Improve Bioavailability and Onset of Action for Highly Lipophilic Cannabinoids

TORONTO– Avicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based pharmaceuticals, announced today positive preclinical results and the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for its proprietary Powder Drug Delivery System, known as PwdRx.

The platform has been specifically designed to address formulation challenges associated with highly lipophilic cannabinoids including CBD, CBG, THC, and CBN which often suffer from poor water solubility, variable absorption, and delayed onset of action.

Preclinical Studies Show Enhanced Absorption Compared to Standard MCT Oil Formulations

In recent in-vitro pharmacokinetic studies, Avicanna’s PwdRx demonstrated statistically significant improvements over conventional medium-chain triglyceride (MCT) oil-based cannabinoid formulations. Key findings include:

• 74% higher bioavailability (AUC)
• 63% faster peak plasma levels (TMAX)
• 134% higher peak plasma concentration (CMAX)

These results suggest that the PwdRx formulation allows cannabinoids to be absorbed more rapidly and consistently, potentially enabling faster therapeutic effects.

Technology Offers Long-Term Stability and Versatile Manufacturing Options

Beyond improved bioavailability, the PwdRx platform is designed to support scalable pharmaceutical production in a variety of solid-oral and powder-based formats, including:

• Tablets
• Capsules
• Sachets
• Pouches

Additionally, the technology offers tunable drug release capabilities, enabling differentiated product profiles to target specific patient needs or therapeutic goals.

Provisional Patent Filing Covers Composition, Methods of Use, and Therapeutic Potential

The provisional patent application includes claims related to the composition, methods of use, and potential clinical utility of the PwdRx platform. The filing highlights applications for pain and inflammation management, including conditions such as:

• Rheumatoid arthritis
• Osteoarthritis
• Neuropathic pain
• Fibromyalgia
• Migraine
• Multiple sclerosis

This step further strengthens Avicanna’s global intellectual property portfolio and demonstrates the company’s ongoing focus on innovation in cannabinoid-based pharmaceuticals.

Leadership Emphasizes Strategic and Commercial Potential

With preclinical success and a provisional patent filing now completed, Avicanna aims to advance the PwdRx platform into clinical development as part of its pharmaceutical pipeline, with the potential to offer differentiated treatments tailored to patient needs.

For more information contact at info@cannabisriskmanager.com